Strategic Collaborations
IsoPlexis has partnered with industry leaders to reveal true functional biology to accelerate research and medicine
IsoPlexis has collaborated with Lonza, a leading cell & gene therapy manufacturer, to use IsoPlexis' IsoLight platform. The automated functional proteomics analysis platform will provide quality analytics for cell therapy products generated on Lonza's Cocoon® Platform, an automated, highly flexible cell therapy manufacturing Platform
A collaboration between IsoPlexis and MD Anderson Cancer Center has found that T-cell cytokine production is linked to response to immunotherapy in leukemia patients. Researchers found that a measure of T-cell functionality strongly predicted response to a novel combination therapy in a set of 10 patients with relapsed acute myeloid leukemia (AML).
IsoPlexis has installed its innovative IsoLight single cell cytokine detection system at the Karolinska Institute in Sweden, as part of its expansion into Europe. This partnership marks a significant milestone for IsoPlexis as they seek to advance both single-cell biology and precision medicine in Europe.
IsoPlexis has placed the IsoLight platform at City of Hope, a world-renowned independent research and treatment center for cancer, diabetes and other life-threatening diseases, providing early access to its innovative platform to leading biopharmaceutical companies, researchers, and trial centers to generate proof of concept data and to solve immediate challenges in the fast moving immune-oncology field and beyond.
In a collaboration with Fred Hutchinson Cancer Center, IsoPlexis has installed its ground-breaking IsoLight benchtop system at Fred Hutchinson Cancer Research Center, as part of the company's Early Adopter Program, in order to continue to improve cellular characterization and correlates in the fast-moving immuno-oncology field and beyond.
